Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim, Toshimi Takano, Seock‐Ah Im, Giuliano Borges, João Paulo da Silveira Nogueira Lima, Sercan Aksoy, Joaquín Gavilá Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruíz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, François P. Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Wu Cai, Changan Chu, Anton Egorov, Ian E. Krop